Jessica Maltman receives a Trainee Professional Development Award (TPDA) to attend the SfN meeting in Chicago (October 2024)
Jessica Maltman receives the Charles C. Clayton VCU School of Medicine Award  (July 2024) 
Justin Silverman selected by VCU-IMSD to receive an NIH R25 fellowship (May 2024)
Psychedelics for mental health: a biomedical perspective (January 2024)
From hallucinations to healing: Neurobiology of psychedelics - TEDx in RVA (November 2023)
How psychedelics in "magic mushrooms" could be used as treatment for depression  (November 2023)
Alaina Jaster receives a Travel Award to attend The International Drug Policy Reform Conference in Phoenix, Arizona (October 2023)
VCU's Inaugural National/International Recognition Award (October 2023)
The Psychedelic Renaissance (August 2023)
Alaina Jaster receives Notice of Award for her F31 fellowship from NIH-NIDA (June 2023)
The Magical Mystery Receptor (May 2023)
Somdatta Saha receives a VCU postdoctoral association Travel Award to attend the 2023 ISSR meeting (April 2023)
Justin Saunders receives a NIDA Travel Award to attend the 2023 ISSR meeting (April 2023)
Psicodélicos para tratar la depresión (April 2023)
Alaina Jaster receives a Travel Award to attend the 15th BBC Translational Research in Substance Use Disorders meeting in San Antonio, Texas (March 2023)
Alaina Jaster as one of the SSDP 30 under 30 women in Psychedelics (March 2023)
Epigenetic roots of long-lasting therapy (October 2022) 
Taking the tripping out of psychedelic medicine (October 2022)
The National Academies released the workshop proceedings "Exploring Psychedelics and Entactogens as Treatment of Psychiatric Disorders"  (September 2022)
Alaina Jaster receives a Travel Award to attend the 2022 INRC meeting in Valencia, Spain (July 2022)
Jason Younkin selected by the VIPGB to receive an NIH-NIMH T32 fellowship (June 2022)
Maya Gaines-Smith selected by VCU-IMSD to receive an NIH R25 fellowship (May 2022)
Psychedelics show promise in treating mental illness (November 2021)
Single dose of a psychedelic drug alters neuron's structure and gene environment (November 2021)
Mario de la Fuente selected by the VIPBG to receive an NIH-NIMH T32 fellowship (November 2020)
Unlocking the mysteries and mechanisms behind psychedelics' antidepressant activity (January 2020)
Magic mushrooms could one day "cure depression", scientists claim (November 2019)
Could psychedelic drugs be a new treatment option for people with depression? (November 2019)
Outstanding teaching award to Javier González-Maeso - VCU School of Medicine (September 2018)
Mario de la Fuente's exhibition a the King's College Science Gallery in London (September 2018)
Justin Saunders receives Notice of Award for his F30 fellowship from NIH-NIMH (September 2018)
Urjita Shah selected to present at the 2018 ISSR meeting (July 2018)
VCU News: Improving brain function in schizophrenia patients (October 2017)
Protecting cognition from antipsychotics (September 2017)
Schizophrenia life sciences poster (September 2017)
Antipsychotics' cognitive side effects have gene-expression underpinnings (August 2017)
Combining science and art the Ingràvid festival in Barcelona
Setas alucinógenas para reducir la depresión en enfermos terminales (April 2017)
Nuevas estrategias para el tratamiento de la esquizofrenia (March 2017)
C&E News: Radiotracer helps neuroscientists study epigenetics in the brain (August 2016)
Mario de la Fuente receives a NIDA Travel Award to attend the 2016 ISSR meeting (July 2016)
Arquitectos de la comunicación celular (March 2016)
Neuroscience News: An alternative treatment target for schizophrenia (February 2016)
Medical Express News: Alternative treatment target for schizophrenia (February 2016)
VCU News: New research suggests alternative treatment target for schizophrenia (February 2016)
Science Signaling Podcast: GPCR heteromers and schizophrenia (January 2016)
Dr. González Maeso joins the Department of Physiology and Biophysics at VCU (July 2015) ​
Baremo para los fármacos antipsicóticos (September 2014)
Comment to "Weighing the evidence for Class A GPCR dimers" (June 2014)
A vital new path for schizophrenia treatment (March 2013)
News and Views in Nature Neuroscience (September 2012)
Comments of Schizophrenia Research Forum about bad behavior  of atypical antipsychotics (August 2012)
Enzyme Inhibitor Might Benefit Schizophrenia Patients (August 2012)
Research Highlights in Nature Reviews Neuroscience (August 2012)
Boosting Antipsychotic Drugs (August 2012)
Epilepsy Drug Boosts Memory (August 2012)
Research Highlights in Nature Medicine (September 2012)
Descubren la razón de la resistencia a los fármacos contra la esquizofrenia (September 2012)
Nuevos Avances en las Bases Bioquímicas de la Esquizofrenia (October 2012)
Leading Edge Previews (November 2011)
Desarrollan un método para predecir si un fármaco es antipsicótico (November 2011)
Clues Emerge About the Maternal Infection Risk Factor for Schizophrenia (February 2011)
A complex in psychosis (March 2008)
​Psychosis drug target (March 2008)
Double GPCR trouble (March 2008)
​Double GPCR trouble (April 2008)
Serotonin-glutamate receptor complex offers new drug target for psychosis (June 2008)
5-HT and Glutamate receptors -- Unique Complex Linked to Psychosis (March 2008)
Descubren una vía para el desarrollo de fármacos contra la esquizofrenia (March 2008)
Científicos de la UPV descubren una nueva vía para combatir la esquizofrenia (February 2008)
Hallan un nuevo tratamiento contra la esquizofrenia (February 2008)
Alucinógenos contra la esquizofrenia (February 2008)
Schizophrenia develops a complex (March 2008)
Descubren la manera en la que los alucinógenos actúan sobre el cerebro (February 2007)
Descubren por qué el LSD es alucinógeno (February 2007)
LSD Study Probes Hallucinogen's Effect on Brain (January 2007)
How Hallucinogens Play Their Mind-Bending Games (January 2007)